Comparison of doses and injection sites of botulinum toxin for chronic anal fissure: A systematic review and network meta-analysis of randomized controlled trials
Open Access
- 1 August 2022
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 104, 106798
Abstract
There are no consensus guidelines on the optimal dose or injection site of botulinum toxin (BT) for chronic anal fissure (CAF). The objective of this study was to determine the appropriate dose and injection site of BT for CAF by comparing healing rate and adverse effects (incontinence and recurrence). MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Scopus were searched from inception through May 31, 2021. Randomized controlled trials evaluating healing and adverse effects of BT injection for CAF published in any language were selected. Multiple treatment comparisons and ranking were performed using a two-stage network meta-analysis, and results were graded by Confidence in Network Meta-Analysis tool. Twenty-seven trials involving 1880 patients were included. The results demonstrated that high-dose-BT had significantly higher short-term healing when injected out of the fissure (OF) site than each side of the fissure (SF) site, with a risk ratio (RR) of 2.12 (1.08, 4.15); low-dose-BT did not show any difference across OF and SF site with RR of 1.20 (0.85, 1.68). High-dose-BT at the OF site showed similar healing to low-dose-BT at the same site (RR of 1.02 (0.79, 1.31)) but with a higher risk of incontinence with RR of 3.54 (0.85, 14.76). In contrast, high-dose-BT at the SF site showed lower healing compared to low-dose-BT at the same site with RR of 0.57 (0.29, 1.14). Both high-dose-BT and low-dose-BT at the OF site had higher recurrence than high-dose-BT or low-dose-BT at the SF site with RR of 2.08 (0.33, 13.11) and 1.89 (0.60, 5.94), respectively. Given moderate level of evidence, low-dose BT is optimal; injection out of the fissure site improves short-term outcomes while injection each side of the fissure site tends to reduce recurrence in the longer term.Keywords
Funding Information
- National Research Council of Thailand (N42A640323)
This publication has 38 references indexed in Scilit:
- Practice Parameters for the Management of Anal Fissures (3rd Revision)Diseases of the Colon & Rectum, 2010
- Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissureBritish Journal of Surgery, 2009
- Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publicationsBMJ, 2009
- Randomized clinical trial comparing botulinum toxin injections with 0·2 per cent nitroglycerin ointment for chronic anal fissureBritish Journal of Surgery, 2007
- Comparison of Glycerine Trinitrate and Botulinum Toxin-A for the Treatment of Chronic Anal Fissure: Long-Term ResultsDiseases of the Colon & Rectum, 2006
- Botulinum neurotoxin to treat chronic anal fissure: results of a randomized ‘Botox vs. Dysport’ controlled trialAlimentary Pharmacology & Therapeutics, 2004
- Comparison of Botulinum Toxin Injection and Lateral Internal Sphincterotomy for the Treatment of Chronic Anal FissureDiseases of the Colon & Rectum, 2003
- Chronic anal fissures treated with botulinum toxin injections: a dose‐finding study with Dysport®Colorectal Disease, 1999
- A Comparison of Botulinum Toxin and Saline for the Treatment of Chronic Anal FissureNew England Journal of Medicine, 1998
- Histopathology of the internal anal sphincter in chronic anal fissureDiseases of the Colon & Rectum, 1989